Hepion Pharmaceuticals Inc (HEPA) — Cash Flow-to-Debt Ratio
Hepion Pharmaceuticals Inc (HEPA) has a Cash Flow-to-Debt Ratio of -0.83x as of December 2025, meaning its operating cash flow of $-332.77K could theoretically repay -1% of its total liabilities ($402.40K) in one year. Check earnings quality score of Hepion Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hepion Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Hepion Pharmaceuticals Inc across 14 annual periods. Also explore HEPA asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hepion Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Hepion Pharmaceuticals Inc. For market capitalisation and broader financial context, see Hepion Pharmaceuticals Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -8.13x | $-3.27 Million | $402.40K | ▼ -55.2% |
| 2024 | -5.24x | $-18.22 Million | $3.48 Million | ▼ -38.6% |
| 2023 | -3.78x | $-40.89 Million | $10.81 Million | ▼ -12.4% |
| 2022 | -3.37x | $-34.96 Million | $10.39 Million | ▼ -13.8% |
| 2021 | -2.96x | $-31.22 Million | $10.56 Million | ▼ -48.7% |
| 2020 | -1.99x | $-16.17 Million | $8.12 Million | ▼ -31.4% |
| 2019 | -1.51x | $-7.57 Million | $4.99 Million | ▲ +39.8% |
| 2018 | -2.52x | $-15.65 Million | $6.21 Million | ▼ -131.6% |
| 2017 | -1.09x | $-8.21 Million | $7.55 Million | ▲ +22.6% |
| 2016 | -1.40x | $-16.56 Million | $11.79 Million | ▲ +71.9% |
| 2015 | -4.99x | $-9.67 Million | $1.94 Million | ▼ -1706.5% |
| 2014 | -0.28x | $-1.36 Million | $4.93 Million | ▲ +0.0% |
| 2013 | -0.28x | $-1.36 Million | $4.93 Million | ▼ -78656.3% |
| 2012 | 0.00x | $-79.70 | $227.21K | — |